Tedizolid is a promising antimicrobial option for the treatment of <i>Staphylococcus aureus</i> infections in cystic fibrosis patients

Abstract

These results suggest that tedizolid represents a promising therapeutic option for the treatment of CF-associated MRSA/MSSA infections, having potent in vivo activity and low resistance potential.